Core Insights - Sequel Med Tech and Senseonics have announced the full availability of the twiist™ Automated Insulin Delivery (AID) System integrated with the Eversense® 365 Continuous Glucose Monitoring (CGM) system across the U.S., marking a significant advancement in diabetes management [1][4]. Company Overview - Sequel Med Tech, headquartered in Manchester, N.H., focuses on developing transformative drug delivery technologies, including the twiist AID system, which aims to simplify disease management [9]. - Senseonics Holdings, Inc. specializes in long-term implantable glucose monitoring products, with the Eversense 365 being the only one-year CGM available, providing continuous glucose monitoring for up to 365 days [10][12]. Product Features - The twiist AID system is the first to be compatible with the Eversense 365 CGM, significantly reducing the need for frequent sensor changes and re-pairing while maintaining high accuracy [2][5]. - The twiist system utilizes the twiist Loop™ algorithm to automatically adjust insulin delivery based on real-time CGM data, offering features like activity presets and a wide glucose target range [7]. Market Impact - The integration of twiist with Eversense 365 is expected to enhance diabetes management by providing users with more tools for glucose control, increased convenience, and greater flexibility [3][4]. - The national availability of this combination is seen as a pivotal moment in reducing the daily burden faced by individuals with diabetes, allowing them to focus more on their lives rather than device management [4][5].

Core Insights - The twiist™ Automated Insulin Delivery (AID) System is now fully available in the U.S., integrated with the Eversense® 365 Continuous Glucose Monitoring (CGM) system, specifically designed for individuals with type 1 diabetes [1][5]. Group 1: Product Features and Benefits - The twiist system is the first AID system compatible with the Eversense 365, which is the only one-year CGM available, significantly reducing the need for frequent sensor changes and re-pairing while maintaining high accuracy [2][5]. - The integration of twiist with Eversense 365 enhances diabetes management by providing tools for better glucose control, increased convenience, and greater flexibility for users [3][4]. - The twiist system features a unique algorithm that automatically adjusts basal insulin delivery based on real-time CGM data, offering personalized diabetes management options [7]. Group 2: Market Impact and Availability - The national availability of the Eversense 365 with twiist marks a significant advancement in diabetes care, allowing users to focus more on their lives rather than device management [4][5]. - Sequel Med Tech aims to provide greater flexibility and choice for individuals managing type 1 diabetes by allowing users to select between two compatible CGM partners: Eversense 365 or Abbott's FreeStyle Libre 3 Plus [4][5]. Group 3: Company Background - Sequel Med Tech, based in Manchester, N.H., is focused on developing transformative drug delivery technologies, with the twiist AID system representing a new standard in insulin delivery [8]. - Senseonics Holdings, Inc. specializes in long-term implantable glucose monitoring technologies, with the Eversense 365 CGM system offering a differentiated experience in diabetes management [9][11].

Company Overview - Tandem Diabetes Care, Inc. (TNDM) has launched its t:slim X2 insulin pump with Control-IQ+ technology, now compatible with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the U.S. An early access program has been initiated, with plans for broader availability in the second half of 2025 [1][9]. Stock Performance - Following the announcement of the new compatibility, TNDM's shares increased by 1.6%, reaching $20.55 [2]. However, over the past year, TNDM shares have experienced a decline of 49.4%, compared to a 14.8% decline in the industry [12]. Financial Metrics - Tandem Diabetes has a market capitalization of $1.35 billion and is projected to have an earnings per share (EPS) growth rate of 28.3% in 2025, significantly higher than the industry's expected growth of 13.8%. Revenue for 2025 is anticipated to rise by 10.6% [4]. Product Features - The t:slim X2 insulin pump utilizes advanced hybrid closed-loop technology, adjusting insulin delivery every five minutes based on predicted glucose values. It features the unique AutoBolus function, which calculates and delivers correction boluses for missed meals [5]. The FreeStyle Libre 3 Plus sensor offers a 15-day wear time and transmits glucose readings every minute to the t:slim mobile app [6]. Industry Insights - The global insulin delivery device market was valued at $16.43 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.9% by 2027, driven by the increasing prevalence of diabetes and advancements in technology [7][10]. Strategic Developments - Tandem Diabetes has entered an agreement to develop integrated diabetes solutions that will combine Abbott's future dual glucose-ketone sensor with Tandem's insulin delivery systems, enhancing options for diabetes management [11].